Saving changes...

Done

Error

Cancer vs Cardiac Cell Killing by Anthracyclines

Cancer vs Cardiac Cell Killing by Anthracyclines

Cancer vs Cardiac Cell Killing by Anthracyclines

Christopher Baines, PhD and Brian Flesner, DVM, MS, DACVIM
Christopher Baines, PhD and Brian Flesner, DVM, MS, DACVIM
on behalf of Missouri Veterinary Medical Association

FREE
FREE
FREE

null FREE
FREE
FREE
null FREE
FREE
FREE
Normal Price: FREE FREE

Review:

Launch date: 30 Jan 2020
Expiry Date:

Last updated: 03 Apr 2020

Reference: 195132

This course is no longer available

Exam is embedded in the course
No preview available
No Exam Available

Latest User Comments

I would like to...

Course Availability

This course is only available to trainees days after purchase. It would need to be repurchased by the trainee if not completed in the allotted time period. This course is no longer available. You will need to repurchase if you wish to take the course again.

You have null days left.

Description

Anthracyclines are commonly used chemotherapeutic agents in both dogs and human; however, their use is greatly hampered by their predilection to induce dilated cardiomyopathy and life-ending arrhythmias. In this presentation we will review the issues regarding the use of anthracyclines in the clinic and the approaches for the diagnosis and current treatment of anthracycline-induced cardiotoxicity. Our current knowledge regarding the cellular mechanisms underlying anthracycline-induced cancer versus cardiac cell death will also be presented. In particular, we will focus on potential new avenues for the development of adjunct therapies to prevent cardiotoxicity while maintaining the cancer killing efficiency of these chemotherapeutics.

Objectives

1. Understand BAG side effects of chemotherapy.
Understand BAG side effects of chemotherapy. Predict when and where typical side effects happen.
Know unique toxicities of doxorubicin, the underlying molecular mechanisms, and potential treatments
Know unique toxicities of doxorubicin, the underlying molecular mechanisms, and potential treatments
3. Be able to describe MDR mutation’s meaning. What drugs are handled by these pumps?
Christopher Baines, PhD and Brian Flesner, DVM, MS, DACVIM

Author Information Play Video Bio

Christopher Baines, PhD and Brian Flesner, DVM, MS, DACVIM
on behalf of Missouri Veterinary Medical Association

Brian K. Flesner, DVM, MS, DACVIM-Oncology
Assistant Professor, Oncology
A graduate of the University of Illinois (DVM) and the University of Missouri (MS), Brian K. Flesner completed an internship at the Veterinary Specialty Hospital in San Diego and his residency at MU. He joined the MU faculty in 2016. Research interests: epigenetics; lymphoma; cancer immunology. Clinical interests: novel treatment approaches to cancer, specifically lymphoma.

Current Accreditations

This course has been certified by or provided by the following Certified Organization/s:

  • Missouri Veterinary Medical Association
  • 0.25 Hours -
    Exam Attempts: 3
    -
    Exam Pass Rate: 60

Faculty and Disclosures

Additional Contributors

Conflicts Declared

Conflicts of Interest declaration by Author:

null

User Reviews (0)

Go Back

Loading...


Saving changes...

Done

Error